Loading...

Raia Drogasil

OTCPK:RADL.Y
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RADL.Y
OTCPK
R$26B
Market Cap
  1. Home
  2. US
  3. Consumer Retailing
Company description

Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines in Brazil. The last earnings update was 83 days ago. More info.


Add to Portfolio Compare Print
  • Raia Drogasil has significant price volatility in the past 3 months.
RADL.Y Share Price and Events
7 Day Returns
0%
OTCPK:RADL.Y
-0.9%
US Consumer Retailing
-1.2%
US Market
1 Year Returns
5.2%
OTCPK:RADL.Y
16.8%
US Consumer Retailing
3.3%
US Market
RADL.Y Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Raia Drogasil (RADL.Y) 0% 11.7% 29.9% 5.2% 13% -
US Consumer Retailing -0.9% 3.1% 8.6% 16.8% 28.9% 43%
US Market -1.2% 0.8% 0.9% 3.3% 35.9% 41.7%
1 Year Return vs Industry and Market
  • RADL.Y underperformed the Consumer Retailing industry which returned 16.8% over the past year.
  • RADL.Y outperformed the Market in United States of America which returned 3.3% over the past year.
Price Volatility
RADL.Y
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Raia Drogasil's competitors could be found in our database.

Value

 Is Raia Drogasil undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Raia Drogasil. This is due to cash flow or dividend data being unavailable. The share price is $21.7.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Raia Drogasil's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Raia Drogasil's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:RADL.Y PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in BRL R$1.43
BOVESPA:RADL3 Share Price ** BOVESPA (2019-07-10) in BRL R$77.5
United States of America Consumer Retailing Industry PE Ratio Median Figure of 23 Publicly-Listed Consumer Retailing Companies 20.52x
United States of America Market PE Ratio Median Figure of 3,082 Publicly-Listed Companies 17.86x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Raia Drogasil.

OTCPK:RADL.Y PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BOVESPA:RADL3 Share Price ÷ EPS (both in BRL)

= 77.5 ÷ 1.43

54.31x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Raia Drogasil is overvalued based on earnings compared to the US Consumer Retailing industry average.
  • Raia Drogasil is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Raia Drogasil's expected growth come at a high price?
Raw Data
OTCPK:RADL.Y PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 54.31x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 13 Analysts
22.5%per year
United States of America Consumer Retailing Industry PEG Ratio Median Figure of 14 Publicly-Listed Consumer Retailing Companies 3.32x
United States of America Market PEG Ratio Median Figure of 2,119 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

OTCPK:RADL.Y PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 54.31x ÷ 22.5%

2.42x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Raia Drogasil is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Raia Drogasil's assets?
Raw Data
OTCPK:RADL.Y PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in BRL R$10.72
BOVESPA:RADL3 Share Price * BOVESPA (2019-07-10) in BRL R$77.5
United States of America Consumer Retailing Industry PB Ratio Median Figure of 32 Publicly-Listed Consumer Retailing Companies 2.03x
United States of America Market PB Ratio Median Figure of 5,248 Publicly-Listed Companies 1.79x
OTCPK:RADL.Y PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BOVESPA:RADL3 Share Price ÷ Book Value per Share (both in BRL)

= 77.5 ÷ 10.72

7.23x

* Primary Listing of Raia Drogasil.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Raia Drogasil is overvalued based on assets compared to the US Consumer Retailing industry average.
X
Value checks
We assess Raia Drogasil's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Consumer Retailing industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Consumer Retailing industry average (and greater than 0)? (1 check)
  5. Raia Drogasil has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Raia Drogasil expected to perform in the next 1 to 3 years based on estimates from 13 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Raia Drogasil expected to grow at an attractive rate?
  • Raia Drogasil's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Raia Drogasil's earnings growth is expected to exceed the United States of America market average.
  • Raia Drogasil's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
OTCPK:RADL.Y Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:RADL.Y Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 13 Analysts 22.5%
OTCPK:RADL.Y Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 13 Analysts 13.2%
United States of America Consumer Retailing Industry Earnings Growth Rate Market Cap Weighted Average 5.8%
United States of America Consumer Retailing Industry Revenue Growth Rate Market Cap Weighted Average 3.9%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:RADL.Y Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below
All numbers in BRL Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:RADL.Y Future Estimates Data
Date (Data in BRL Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 28,054 1,443 1
2022-12-31 25,788 1,520 1,102 4
2021-12-31 22,748 1,378 833 10
2020-12-31 19,866 1,185 672 13
2019-12-31 17,062 952 522 13
OTCPK:RADL.Y Past Financials Data
Date (Data in BRL Millions) Revenue Cash Flow Net Income *
2019-03-31 15,321 708 470
2018-12-31 14,801 683 502
2018-09-30 14,306 570 519
2018-06-30 13,966 674 527
2018-03-31 13,589 691 528
2017-12-31 13,213 629 511
2017-09-30 12,768 601 464
2017-06-30 12,252 603 444
2017-03-31 11,798 597 462
2016-12-31 11,257 556 448
2016-09-30 10,658 528 438
2016-06-30 10,042 390 407

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Raia Drogasil's earnings are expected to grow significantly at over 20% yearly.
  • Raia Drogasil's revenue is expected to grow by 13.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:RADL.Y Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below

All data from Raia Drogasil Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:RADL.Y Future Estimates Data
Date (Data in BRL Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31 3.27 3.27 3.27 1.00
2021-12-31 2.61 2.85 2.54 6.00
2020-12-31 2.09 2.67 1.91 8.00
2019-12-31 1.57 1.59 1.55 5.00
OTCPK:RADL.Y Past Financials Data
Date (Data in BRL Millions) EPS *
2019-03-31 1.43
2018-12-31 1.53
2018-09-30 1.58
2018-06-30 1.60
2018-03-31 1.60
2017-12-31 1.55
2017-09-30 1.41
2017-06-30 1.35
2017-03-31 1.40
2016-12-31 1.36
2016-09-30 1.33
2016-06-30 1.23

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Raia Drogasil is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Raia Drogasil's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Raia Drogasil has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Raia Drogasil performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Raia Drogasil's growth in the last year to its industry (Consumer Retailing).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Raia Drogasil has delivered over 20% year on year earnings growth in the past 5 years.
  • Raia Drogasil's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Raia Drogasil's 1-year earnings growth is negative, it can't be compared to the US Consumer Retailing industry average.
Earnings and Revenue History
Raia Drogasil's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Raia Drogasil Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:RADL.Y Past Revenue, Cash Flow and Net Income Data
Date (Data in BRL Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 15,321.22 470.00 3,813.94
2018-12-31 14,801.45 502.45 3,664.46
2018-09-30 14,305.68 519.13 3,177.22
2018-06-30 13,965.70 527.24 3,023.60
2018-03-31 13,588.97 528.26 3,368.63
2017-12-31 13,212.51 511.16 3,195.63
2017-09-30 12,768.21 463.96 3,032.31
2017-06-30 12,252.30 443.74 2,708.62
2017-03-31 11,798.25 461.54 2,630.00
2016-12-31 11,256.57 447.69 2,516.49
2016-09-30 10,657.82 438.47 2,382.11
2016-06-30 10,042.06 406.94 2,244.47
2016-03-31 9,445.71 359.88 2,103.17
2015-12-31 8,897.85 340.21 1,977.18
2015-09-30 8,447.75 325.01 1,855.24
2015-06-30 8,073.87 308.69 1,755.11
2015-03-31 7,668.38 262.58 1,667.35
2014-12-31 7,351.46 221.39 1,604.03
2014-09-30 7,023.28 187.05 1,541.80
2014-06-30 6,737.52 137.69 1,500.41
2014-03-31 6,495.12 115.84 1,429.01
2013-12-31 6,207.17 100.99 1,364.54
2013-09-30 5,979.48 74.57 1,319.59
2013-06-30 5,749.17 90.69 1,251.69
2013-03-31 5,532.87 99.75 1,218.91
2012-12-31 2,976.05 104.86 611.05
2012-09-30 4,992.76 110.68 1,070.24

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Raia Drogasil has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Raia Drogasil used its assets less efficiently than the US Consumer Retailing industry average last year based on Return on Assets.
  • Raia Drogasil's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Raia Drogasil's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Consumer Retailing industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Raia Drogasil has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Raia Drogasil's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Raia Drogasil's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Raia Drogasil is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Raia Drogasil's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Raia Drogasil's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Raia Drogasil Company Filings, last reported 3 months ago.

OTCPK:RADL.Y Past Debt and Equity Data
Date (Data in BRL Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 3,571.44 1,078.29 243.60
2018-12-31 3,534.77 843.15 241.57
2018-09-30 3,394.86 903.13 273.56
2018-06-30 3,314.66 911.62 281.26
2018-03-31 3,224.39 573.51 102.68
2017-12-31 3,250.37 610.96 264.87
2017-09-30 3,112.05 718.49 394.56
2017-06-30 3,023.25 753.66 324.36
2017-03-31 2,930.40 473.41 181.60
2016-12-31 2,935.96 413.97 276.63
2016-09-30 2,838.42 360.08 255.83
2016-06-30 2,767.76 323.14 56.50
2016-03-31 2,655.48 293.69 106.77
2015-12-31 2,656.80 296.39 266.05
2015-09-30 2,574.80 255.12 268.79
2015-06-30 2,528.80 263.91 210.93
2015-03-31 2,495.42 255.02 230.87
2014-12-31 2,456.94 281.24 281.19
2014-09-30 2,406.16 222.00 149.77
2014-06-30 2,360.18 244.77 143.51
2014-03-31 2,348.38 259.90 139.14
2013-12-31 2,326.98 244.83 241.89
2013-09-30 2,304.87 183.81 122.37
2013-06-30 2,291.75 192.87 73.56
2013-03-31 2,275.54 201.94 127.01
2012-12-31 2,264.66 192.17 166.96
2012-09-30 2,255.02 148.96 218.40
  • Raia Drogasil's level of debt (132.2%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (11.1% vs 132.2% today).
  • Debt is not well covered by operating cash flow (15%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 14.4x coverage).
X
Financial health checks
We assess Raia Drogasil's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Raia Drogasil has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Raia Drogasil's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.82%
Current annual income from Raia Drogasil dividends. Estimated to be 1.32% next year.
If you bought $2,000 of Raia Drogasil shares you are expected to receive $16 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Raia Drogasil's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).
  • Raia Drogasil's dividend is below the markets top 25% of dividend payers in United States of America (3.78%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:RADL.Y Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below
United States of America Consumer Retailing Industry Average Dividend Yield Market Cap Weighted Average of 12 Stocks 1.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:RADL.Y Future Dividends Estimate Data
Date (Data in R$) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31 3.18 1.00
2021-12-31 1.15 8.00
2020-12-31 0.91 10.00
2019-12-31 0.80 9.00
OTCPK:RADL.Y Past Annualized Dividends Data
Date (Data in R$) Dividend per share (annual) Avg. Yield (%)
2019-02-27 0.636 0.915
2019-02-26 0.636 1.008
2018-02-22 0.614 0.901
2017-02-16 0.607 0.837
2016-10-27 0.598 0.945
2015-02-26 0.226 0.536
2014-03-17 0.118 0.554
2013-11-07 0.067 0.435
2013-08-09 0.194 1.112
2013-08-08 0.194 1.011
2013-05-10 0.041 0.194
2013-05-09 0.041 0.184
2013-04-11 0.000 0.000
2013-03-28 0.000 0.000
2013-03-27 0.000 0.000
2012-05-10 0.085 0.388
2012-03-28 0.179 0.932
2012-03-27 0.179 1.009
2011-11-10 0.000 0.000
2011-03-01 0.116 1.004
2011-02-24 0.116 0.926
2010-03-02 0.137 1.164
2009-03-04 0.107 1.740
2009-01-15 0.107 3.686

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Raia Drogasil's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (2.2x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be covered by earnings (1.7x coverage).
X
Income/ dividend checks
We assess Raia Drogasil's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Raia Drogasil afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Raia Drogasil has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Raia Drogasil's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Marcílio Pousada
AGE 54
TENURE AS CEO 6 years
CEO Bio

Mr. Marcílio D'Amigo Pousada has been the Chief Executive Officer of Raia Drogasil S.A. since July 1, 2013 and serves as its Member of Board Executive Director. Mr. Pousada serves as the Chief Executive Officer of Saraiva E Siciliano S.A. He served as the Chief Executive Officer of Saraiva S.A. Livreiros Editores. He serves as a Superintendent Director at Saraiva S.A. Livreiros Editores.

CEO Compensation
  • Insufficient data for Marcílio to compare compensation growth.
  • Insufficient data for Marcílio to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team

Marcílio Pousada

TITLE
CEO & Member of Board Executive Director
AGE
54
TENURE
6 yrs

Antonio Coelho

TITLE
CFO & Member of Executive Board

Antonio Carlos de Freitas

TITLE
Director of Retail Operations - Drogasil and Member of Executive Board
TENURE
20.5 yrs

Eugênio De Zagottis

TITLE
Corporate Planning & Investor Relations Officer and Member of Executive Board

Marcello De Zagottis

TITLE
Sales & Marketing Officer and Member of Executive Board

Fernando Varela

TITLE
Supply Chain & IT Officer and Member of Executive Board

Renato Raduan

TITLE
Director of Retail Operations & Member of Executive Board

Maria De Souza

TITLE
Human Resources Officer & Member of Executive Board
Board of Directors Tenure

Average tenure of the Raia Drogasil board of directors in years:

17.5
Average Tenure
  • The average tenure for the Raia Drogasil board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Antonio Pipponzi

TITLE
Chairman of the Board

Eugênio De Zagottis

TITLE
Corporate Planning & Investor Relations Officer and Member of Executive Board

Carlos Oliveira Dias

TITLE
Director
AGE
68
TENURE
25.5 yrs

Renato Oliveira Dias

TITLE
Director
TENURE
17.5 yrs

Jairo Loureiro

TITLE
Independent Director
TENURE
12.5 yrs

Paulo Coutinho Galvão Filho

TITLE
Director
TENURE
25.5 yrs

Cristiana Pipponzi

TITLE
Director
TENURE
6.3 yrs

Plínio Musetti

TITLE
Director
AGE
66

Marcelo José E Silva

TITLE
Independent Director

Marco Ambrogio Bonomi

TITLE
Independent Director
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Raia Drogasil's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Raia Drogasil has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines in Brazil. As of December 31, 2017, it operated through a network of 1,610 drugstores under the Raia, Drogasil, and Farmasil brands in 20 states of Brazil. The company was founded in 1905 and is headquartered in São Paulo, Brazil.

Details
Name: Raia Drogasil S.A.
RADL.Y
Exchange: OTCPK
Founded: 1905
R$6,825,347,351
329,624,646
Website: http://www.rd.com.br
Address: Raia Drogasil S.A.
Av. Corifeu de Azevedo Marques, 3097,
Butantã,
São Paulo,
São Paulo, 05339-000,
Brazil
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BOVESPA RADL3 Common Shares Bolsa de Valores de Sao Paulo BR BRL 26. Nov 2008
OTCPK RADL.Y SPONSORED ADR Pink Sheets LLC US USD 27. Apr 2016
Number of employees
Current staff
Staff numbers
36,192
Raia Drogasil employees.
Industry
Drug Retail
Consumer Retailing
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/22 03:14
End of day share price update: 2019/07/10 00:00
Last estimates confirmation: 2019/07/20
Last earnings filing: 2019/04/30
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.